TMCnet News
Sage Therapeutics to Report Third Quarter 2016 Financial Results on Thursday, November 3, 2016Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a conference call and live webcast on Thursday, November 3, 2016 at 8:00 am ET to report its third quarter 2016 financial results and discuss recent business updates. The live webcast can be accessed on the investor page of Sage's website at investor.sagerx.com. The conference call can be accessed by dialing 1-866-450-8683 (toll-free omestic) or 1-281-542-4847 (international) and using the conference ID 4543484. A replay of the webcast will be available on Sage's website approximately two hours after the completion of the event and will be archived for up to 30 days. About Sage Therapeutics Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and is being developed for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders. For more information, please visit www.sagerx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006944/en/ |
